Highlights
The INSIGHT study confirms that twice-daily bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF) achieves 94 percent viral suppression at week 24 in patients with HIV receiving rifampicin-based tuberculosis treatment. No treatment failures or emergent resistance were observed in the bictegravir group, highlighting its robust genetic barrier even in the presence of potent enzyme inducers. Furthermore, the safety profile was manageable, with grade 3 or higher adverse events comparable between the bictegravir and dolutegravir-based control arms, suggesting that BID dosing is a viable clinical strategy for this complex patient population.
